Auris, nasus, larynx · 2020
Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Inoue Hiroto, Yokota Tomoya, Hamauchi Satoshi, Onozawa Yusuke, Kawakami Takeshi, Shirasu Hiromichi, Notsu Akifumi, Yasui Hirofumi, Onitsuka Tetsuro
Аннотация
OBJECTIVE: Baseline tumor size has been reported to be predictive of immune checkpoint inhibitor efficacy in melanoma and lung cancer. We investigated whether pre-treatment tumor size (PTS) is predictive of progression-free survival (PFS) and tumor shrinkage in head and neck squamous cell carcinoma (HNSCC) patients treated with nivolumab.
METHODS: We retrospectively assessed 37 patients who had measurable tumor lesions. PTS and post-treatment tumor size were defined as the sum of the size in all measurable lesions.
RESULTS: In univariate analysis, PTS below 42 mm, history of radiation therapy, and no use of cetuximab were significantly associated with longer PFS. Among them, small-PTS was an independent predictive factor for PFS in multivariate analysis (hazard ratio: 0.33, p = 0.022). In addition, significantly greater tumor shrinkage was observed for small-PTS than large-PTS (median: -10.0% vs. 23.1%, p = 0.033).
CONCLUSION: PTS may impact the response to nivolumab in HNSCC patients.
METHODS: We retrospectively assessed 37 patients who had measurable tumor lesions. PTS and post-treatment tumor size were defined as the sum of the size in all measurable lesions.
RESULTS: In univariate analysis, PTS below 42 mm, history of radiation therapy, and no use of cetuximab were significantly associated with longer PFS. Among them, small-PTS was an independent predictive factor for PFS in multivariate analysis (hazard ratio: 0.33, p = 0.022). In addition, significantly greater tumor shrinkage was observed for small-PTS than large-PTS (median: -10.0% vs. 23.1%, p = 0.033).
CONCLUSION: PTS may impact the response to nivolumab in HNSCC patients.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalCetuximabFemaleHead and Neck NeoplasmsHumansImmune Checkpoint InhibitorsLung NeoplasmsLymph NodesLymphatic MetastasisMaleMiddle AgedNivolumabProgression-Free SurvivalRadiotherapyRetrospective StudiesSquamous Cell Carcinoma of Head and NeckTumor Burden